PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.52%
Both yoy net incomes decline, with VET at -25.63%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
4.52%
Some D&A expansion while VET is negative at -2.94%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-32.86%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
1999.85%
Well above VET's 6.78% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1999.85%
Growth well above VET's 6.78%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-206.74%
Negative yoy while VET is 2863.74%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-32.85%
Both yoy CFO lines are negative, with VET at -4.21%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
15.48%
Lower CapEx growth vs. VET's 64.46%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
206.97%
Growth well above VET's 114.81%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
194.71%
Investing outflow well above VET's 76.80%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
46.76%
Debt repayment growth of 46.76% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
114.50%
We slightly raise equity while VET is negative at -56.51%. John Neff sees competitor possibly preserving share count or buying back shares.
-44431.11%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.